(Reuters) - A supplemental NDA is used to obtain an add-on approval for
a therapy already approved for another use. Vyvanse, a
once-a-day capsule, is already approved to treat ADHD in
children aged 6 years to 12 years.
"We are pleased with the results of Vyvanse studies
conducted in adults...", Chief Executive Matthew Emmens said in
a news release, adding that this drug is a priority in the
company's ADHD portfolio.
Read more at Reuters.com Government Filings News
a therapy already approved for another use. Vyvanse, a
once-a-day capsule, is already approved to treat ADHD in
children aged 6 years to 12 years.
"We are pleased with the results of Vyvanse studies
conducted in adults...", Chief Executive Matthew Emmens said in
a news release, adding that this drug is a priority in the
company's ADHD portfolio.
Read more at Reuters.com Government Filings News
No comments:
Post a Comment